Trials / Completed
CompletedNCT04335136
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 185 (actual)
- Sponsor
- Apeiron Biologics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RhACE2 APN01 | Patients will be treated with APN01 intravenously twice daily (BID). |
| DRUG | Physiological saline solution | Patients will be treated with placebo intravenously twice daily (BID). |
Timeline
- Start date
- 2020-04-30
- Primary completion
- 2020-12-26
- Completion
- 2020-12-26
- First posted
- 2020-04-06
- Last updated
- 2021-08-02
- Results posted
- 2021-08-02
Locations
22 sites across 5 countries: Austria, Denmark, Germany, Russia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04335136. Inclusion in this directory is not an endorsement.